title: [Effects of Tankejing dry powder inhaler on the inflammatory damage in the lungs of mice infected by FM1].
abstract: OBJECTIVE
  To study the effect of Tankejing Dry Powder inhaler on inflammatory in lung injury of mice infected by influenza virus (FM1).
  
  
  METHODS
  Model mice infected by influenza virus FM1 were randomly divided into six groups: the nomal group, model group, low dose, medium dose and high dose of Tankejing Dry Powder inhaler group,and Ribavirin group. The following indices including the change of NF-kappaB in lung tissue at 24 h, the changes of TNF-alpha, IL-1beta, IL-6 in lung tissue, the lung index and the death rate were observed.
  
  
  RESULTS
  Compared with model group, medium and high dosages of Tankejing Dry Powder inhaler could modulate the expression of NF-kappaB, reduce the level of TNF-alpha, IL-beta, IL-6 in lung tissue (P < 0.05), and reduce the lung index and the death number of animals within 14 days (P < 0.05).
  
  
  CONCLUSIONS
  Tankejing Dry Powder inhaler may reduce the inflammatory injury caused by influenza virus FM1 through regulating the expression level of NF-kappaB and cytokine.
authors.affiliation: Guangdong Food and Drug Vocational College, Guangzhou 510520, China.
authors.forename: Yong-Nan
authors.initials: YN
authors.lastname: Jiang
authors.forename: Hong-Ying
authors.initials: HY
authors.lastname: Mo
mesh_terms: D000818:Animals; D015153:Blotting, Western; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007375:Interleukin-1 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008168:Lung / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016328:NF-kappa B / Q000378:metabolism*; D009976:Orthomyxoviridae Infections / Q000378:metabolism* / Q000821:virology; D010946:Plants, Medicinal / Q000737:chemistry; D011024:Pneumonia, Viral / Q000378:metabolism / Q000473:pathology*; D011208:Powders; D011897:Random Allocation; D012254:Ribavirin / Q000008:administration & dosage / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D007375:Interleukin-1; D015850:Interleukin-6; D016328:NF-kappa B; D011208:Powders; D014409:Tumor Necrosis Factor-alpha; D012254:Ribavirin